ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney (Nasdaq: PROK), a late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has announced its participation in two major healthcare conferences in September 2025.
The company will present at the Citi Biopharma Back to School Conference in Boston on September 3 at 10:30am ET, and the Morgan Stanley Global Healthcare Conference in New York on September 8 at 7:00am ET. Both presentations will be in a fireside chat format and available via webcast through ProKidney's investor relations website.
ProKidney (Nasdaq: PROK), azienda in fase clinica avanzata specializzata in terapie cellulari per la malattia renale cronica (CKD), ha annunciato la sua partecipazione a due importanti conferenze sanitarie a settembre 2025.
La società presenterà al Citi Biopharma Back to School Conference a Boston il 3 settembre alle 10:30 ET e al Morgan Stanley Global Healthcare Conference a New York l'8 settembre alle 7:00 ET. Entrambe le presentazioni saranno in formato fireside chat e saranno trasmesse in webcast tramite il sito delle relazioni con gli investitori di ProKidney.
ProKidney (Nasdaq: PROK), una compañía en fase clínica avanzada especializada en terapias celulares para la enfermedad renal crónica (CKD), ha anunciado su participación en dos importantes conferencias de salud en septiembre de 2025.
La empresa presentará en el Citi Biopharma Back to School Conference en Boston el 3 de septiembre a las 10:30 ET y en el Morgan Stanley Global Healthcare Conference en Nueva York el 8 de septiembre a las 7:00 ET. Ambas presentaciones serán en formato fireside chat y estarán disponibles por webcast a través del sitio web de relaciones con inversores de ProKidney.
ProKidney (나스닥: PROK)는 만성 신장 질환(CKD)을 전문으로 하는 후기 임상 단계의 세포 치료제 기업으로, 2025년 9월 두 건의 주요 헬스케어 콘퍼런스에 참가한다고 발표했습니다.
회사는 9월 3일 오전 10:30(동부시간)에 보스턴에서 열리는 Citi Biopharma Back to School Conference와 9월 8일 오전 7:00(동부시간)에 뉴욕에서 열리는 Morgan Stanley Global Healthcare Conference에서 발표할 예정입니다. 두 발표 모두 파이어사이드 채트 형식으로 진행되며 ProKidney 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
ProKidney (Nasdaq: PROK), une société en phase clinique avancée spécialisée dans les thérapies cellulaires pour la maladie rénale chronique (CKD), a annoncé sa participation à deux grandes conférences de santé en septembre 2025.
La société interviendra au Citi Biopharma Back to School Conference à Boston le 3 septembre à 10h30 ET, et au Morgan Stanley Global Healthcare Conference à New York le 8 septembre à 7h00 ET. Les deux présentations se dérouleront sous forme de fireside chat et seront diffusées en webcast via le site des relations investisseurs de ProKidney.
ProKidney (Nasdaq: PROK), ein spätklinisches Unternehmen für zelluläre Therapien mit Schwerpunkt auf chronischer Nierenerkrankung (CKD), hat seine Teilnahme an zwei wichtigen Gesundheitskonferenzen im September 2025 angekündigt.
Das Unternehmen wird am Citi Biopharma Back to School Conference in Boston am 3. September um 10:30 Uhr ET und am Morgan Stanley Global Healthcare Conference in New York am 8. September um 07:00 Uhr ET präsentieren. Beide Vorträge finden im Fireside-Chat-Format statt und werden per Webcast über die Investor-Relations-Website von ProKidney verfügbar sein.
- None.
- None.
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September:
| Citi Biopharma Back to School Conference (Boston) | |
| Date: | Wednesday, September 3, 2025 |
| Time: | 10:30am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
| Morgan Stanley Global Healthcare Conference (New York) | |
| Date: | Monday, September 8, 2025 |
| Time: | 7:00am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
The live webcasts of the fireside chats will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their banking representatives.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) presenting at the Citi Biopharma Conference 2025?
When is ProKidney's presentation at the Morgan Stanley Healthcare Conference 2025?
How can investors access ProKidney's (PROK) conference presentations?
What is ProKidney's (PROK) main focus as a company?
